FDA FAERS Reports – ELEVIDYS (Sarepta) Sep–Oct 2024

FDA FAERS Reports – ELEVIDYS (Sarepta) Sep–Oct 2024

Regular price $69.00 USD
Regular price Sale price $69.00 USD
Sale Sold out
Original Request: I would like to request full reports of any and all adverse events reported to the FAERS database for ELEVIDYS (branded name / marketed by Sarepta Therapeutics, Inc.) or delandistrogene moxeparvovec-rokl (generic name) between  September 26, 2024 and October 26, 2024. Please provide the documents electronically if possible.
  • Status: Pending Fast-Track Request
  • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

View full details